Besides exhibiting an elevated basal level of IL-6, tumor perivascular-like cells also show an enhanced expression of the IFNγ-inducible immunosuppressive ligand PD-L1, which in advanced NSCLC may represent a novel biomarker for immune checkpoint blockade therapy31, 32. This evidence concerns the gene IL6 and non-small cell lung carcinoma.